Jefferies Financial Group initiated coverage on shares of Cybin (NASDAQ:HELP – Free Report) in a research note issued to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $22.00 price target on the stock.
Cybin Price Performance
NASDAQ HELP opened at $6.87 on Monday. Cybin has a 12-month low of $4.81 and a 12-month high of $10.72. The company has a quick ratio of 8.58, a current ratio of 8.58 and a debt-to-equity ratio of 0.21.
Cybin Company Profile
Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.
The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.
See Also
- Five stocks we like better than Cybin
- The day the gold market broke
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Forget AI, This Will Be the Next Big Tech Breakthrough
- Gold’s getting scarce.
- End of America Update
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
